Skip to main content

Table 1 Mouse causal prophylaxis experiments

From: Anti-relapse activity of mirincamycin in the Plasmodium cynomolgi sporozoite-infected Rhesus monkey model

DRUG (SC or PO)

Dose (mg/kg/day)

No. inoculated

No. 100% protected

Day of parasitaemia

Exp#

None

0.00

35

0

4-to-5

179

Clindamycin (SC)

10.00

5

0

6-to-7

179

 

40.00

5

3

10,10

179

Mirincamycin (racemate: 65% trans) (SC)

1.10

5

3

10,10

180

 

3.30

5

5

na

180

cis-Mirincamycin (SC)

1.10

5

5

na

180

 

3.30

5

5

na

180

trans-Mirincamycin (SC)

1.10

5

3

10,10

179

 

3.30

5

5

na

179

Lincomycin (SC)

1.1-to-40

5

0

4-to-5

200

cis-Mirincamycin (SC)

0.14

5

0

5-to-6

204

 

0.28

5

0

6-to-8

204

 

0.55

5

3

7,9

204

 

1.10

5

4

7

204

cis-Mirincamycin (SC)

0.14

5

0

4-to-6

205

 

0.28

5

0

6-to-8

205

 

0.55

5

0

7-to-10

205

 

1.10

5

3

10,10

205

Mirincamycin (racemate: 65% trans) (PO)

1.10

5

0

7-to-9

208

 

3.30

5

3

7-to-8

208

 

10.00

5

5

na

208

 

40.00

5

5

na

208

cis-Mirincamycin (PO)

1.10

5

0

7-to-8

208

 

3.30

5

5

na

208

 

10.00

5

3

7-to-8

208

 

40.00

5

5

na

208

cis-Mirincamycin (PO)

2

5

1

7--11

234

 

3.3

5

5

na

234

 

10

5

5

na

234

trans-Mirincamycin (PO)

1.10

5

0

7

206

 

3.30

5

5

na

206

 

10.00

5

5

na

206

 

40.00

5

5

na

206

trans-Mirincamycin (PO)

2

5

2

7--8

234

 

3.3

5

4

10

234

 

10

5

5

na

234